オリゴヌクレオチド合成市場 : 2027年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年11月

オリゴヌクレオチド合成市場 : 製品 [医薬品、合成オリゴ (プライマー)、試薬]、タイプ (カスタム、設計済み)、用途 [治療 (ASO、siRNA)、研究 (PCR、シーケンス、診断)]、エンドユーザー (製薬、CROS、CMO) – 2027年までの世界予測
Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research ((PCR, Sequencing, Diagnostics)), End User (Pharma, CROS, CMOs) – Global Forecast to 2027

ページ数 297
図表数 411
種別 英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The global oligonucleotide synthesis market is projected to reach USD 16.7 billion by 2027 from USD 7.7 billion in 2022, at a CAGR of 16.8% during the forecast period. Market growth can be attributed to the increasing ongoing clinical trials for oligonucleotide-based therapies for leading therapeutic areas such as oncology.

オリゴヌクレオチド合成市場 : 製品 [医薬品、合成オリゴ (プライマー)、試薬]、タイプ (カスタム、設計済み)、用途 [治療 (ASO、siRNA)、研究 (PCR、シーケンス、診断)]、エンドユーザー (製薬、CROS、CMO) - 2027年までの世界予測
“The primers segment will grow at the highest rate in the synthesized oligos market, by product”
By product, the synthesized oligonucleotides market segment is divided into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. Primers are expected to show the highest growth over the forecast period owing to their wide applications in PCR, sequencing, gene synthesis, and cloning.
“By therapeutic application, the antisense oligonucleotide-based therapies segment accounted for the largest share of the oligonucleotide synthesis market in 2021”
The therapeutic application segment is further segmented into antisense oligonucleotide-based therapies, siRNA oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. In 2021, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.
Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), Kaneka Corporation (Japan), Biolegio B.V. (Netherlands), Biolytic Lab Performance Inc. (US), Microsynth AG (Switzerland), ATDBio Ltd. (UK), Twist Bioscience Corporation (US), Eton Bioscience, Inc. (US), CSBIO (US), Tag Copenhagen A/S (Denmark), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), and Alnylam Pharmaceuticals, Inc. (US) are some of the major players operating in the market.

“Asia Pacific region will register a highest CAGR in the oligonucleotide synthesis market”
The market for oligonucleotide synthesis in Asia Pacific is anticipated to develop at the fastest rate during the forecast period. Growing R&D funding and research activity, increased product availability and decreased outsourcing costs are some of the factors that are likely to propel market growth.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side – 20%
• By Designation: Managers- 45%, CXOs, and Director level – 30%, and Executives – 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• LGC Limited (UK)
• Maravai Life Sciences (US)
• Agilent Technologies, Inc. (US)
• Eurofins Scientific (Germany)
• Kaneka Corporation (Japan)
• Biolegio B.V. (Netherlands)
• Biolytic Lab Performance Inc. (US)
• Microsynth AG (Switzerland)
• ATDBio Ltd. (UK)
• Twist Bioscience Corporation (US)
• Eton Bioscience, Inc. (US)
• CSBIO (US)
• Tag Copenhagen A/S (Denmark)
• Generi Biotech (Czech Republic)
• Biocomma Limited (China)
• Hongene Biotech Corporation (China)
• Hangzhou pharm &chem Co., Ltd (China)
• Tokyo Chemical Industry Co., Ltd. (Japan)
• Biogen Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Ionis Pharmaceuticals, Inc. (US)
• Alnylam Pharmaceuticals, Inc. (US)

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research ((PCR, Sequencing, Diagnostics)), End User (Pharma, CROS, CMOs) - Global Forecast to 2027

Research Coverage:
This report provides a detailed picture of the oligonucleotide synthesis market. It aims to estimate the market’s size and future growth potential across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.


目次

1 INTRODUCTION 49
1.1 STUDY OBJECTIVES 49
1.2 MARKET DEFINITION 49
1.2.1 INCLUSIONS AND EXCLUSIONS 50
1.3 MARKET SCOPE 51
1.3.1 MARKETS COVERED 51
1.3.2 YEARS CONSIDERED 52
1.4 CURRENCY CONSIDERED 52
1.5 LIMITATIONS 52
1.6 STAKEHOLDERS 53
1.7 SUMMARY OF CHANGES 53
2 RESEARCH METHODOLOGY 54
2.1 RESEARCH DATA 54
FIGURE 1 RESEARCH DESIGN 54
2.1.1 SECONDARY DATA 54
2.1.2 PRIMARY DATA 55
FIGURE 2 BREAKDOWN OF PRIMARIES 56
2.2 MARKET ESTIMATION METHODOLOGY 57
FIGURE 3 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (RESEARCH AND DIAGNOSTIC MARKET) 57
FIGURE 4 MARKET SIZE ESTIMATION- COMPANY REVENUE ANALYSIS-BASED ESTIMATION (THERAPEUTIC MARKET) 57
FIGURE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE (USD MILLION) 58
FIGURE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: FINAL CAGR PROJECTIONS (2022−2027) 58
FIGURE 7 OLIGONUCLEOTIDE SYNTHES MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59
FIGURE 8 OLIGONUCLEOTIDE SYNTHESIS: SEGMENTAL ASSESSMENT 60
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 60
FIGURE 9 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 60
2.3 DATA TRIANGULATION 61
FIGURE 10 DATA TRIANGULATION METHODOLOGY 61
2.4 STUDY ASSUMPTIONS 62
2.5 RISK ANALYSIS 62
3 EXECUTIVE SUMMARY 63
FIGURE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 63
FIGURE 12 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 64
FIGURE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 64
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET 65
4 PREMIUM INSIGHTS 66
4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW 66
FIGURE 15 INCREASING USE OF SYNTHETIC OLIGOS TO DRIVE MARKET 66
4.2 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION AND COUNTRY (2021) 67
FIGURE 16 THERAPEUTIC APPLICATION SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021 67
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY PRODUCT, 2022 VS. 2027 67
FIGURE 17 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2027 67
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2022 68
FIGURE 18 THERAPEUTIC APPLICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022 68
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
FIGURE 19 ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 68
5 MARKET OVERVIEW 69
5.1 INTRODUCTION 69
5.2 MARKET DYNAMICS 69
FIGURE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 69
5.2.1 DRIVERS 70
5.2.1.1 Increasing use of synthesized oligos in therapeutic applications 70
TABLE 1 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES 70
FIGURE 21 ONGOING CLINICAL TRIALS BY TOP 10 THERAPEUTIC AREAS 71
5.2.1.2 Increasing government investments in synthetic biology and genome projects 71
5.2.1.3 Growing focus on personalized medicine 72
5.2.2 RESTRAINTS 72
5.2.2.1 Complexities associated with therapeutic oligos 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Increasing R&D investments by key players in emerging economies 73
5.2.4 CHALLENGES 74
5.2.4.1 Delivery of oligonucleotide drugs to specific targets 74
5.3 RANGES/SCENARIOS 75
FIGURE 22 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF OLIGONUCLEOTIDE SYNTHESIS MARKET 75
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 76
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS 76

5.5 SUPPLY CHAIN ANALYSIS 76
FIGURE 24 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES 77
5.5.1 KEY INFLUENCERS 77
5.6 VALUE CHAIN ANALYSIS 78
FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 78
5.7 ECOSYSTEM ANALYSIS 78
FIGURE 26 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET 78
5.7.1 ROLE IN ECOSYSTEM 79
5.8 TECHNOLOGICAL ANALYSIS 79
5.8.1 SOLID-PHASE SYNTHESIS 79
5.8.2 LIQUID-PHASE SYNTHESIS 79
5.9 INDICATIVE PRICING MODEL ANALYSIS 80
TABLE 2 PRICING ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 80
5.10 TRADE DATA 81
TABLE 3 IMPORT DATA FOR OLIGONUCLEOTIDES, BY COUNTRY, 2016–2020 (USD THOUSAND) 81
5.11 REGULATORY ANALYSIS 84
5.11.1 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS 84
5.11.2 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS: GOOD MANUFACTURING PRACTICES (GMP) 85
5.11.3 ISO 13485 85
5.11.4 IVD & ASR 85
5.12 PATENT ANALYSIS 86
FIGURE 27 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012–OCTOBER 2022) 86
TABLE 4 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 87
5.13 PORTER’S FIVE FORCES ANALYSIS 88
TABLE 5 PORTER’S FIVE FORCES ANALYSIS 88
5.13.1 DEGREE OF COMPETITION 88
5.13.2 BARGAINING POWER OF SUPPLIERS 88
5.13.3 BARGAINING POWER OF BUYERS 88
5.13.4 THREAT OF SUBSTITUTES 88
5.13.5 THREAT OF NEW ENTRANTS 88
5.14 KEY CONFERENCES AND EVENTS IN 2022–2023 89
TABLE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES AND EVENTS 89
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 89
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 89
5.16 KEY BUYING CRITERIA BY END USERS 90
FIGURE 29 BUYING CRITERIA OF END USERS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 90
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT 91
6.1 INTRODUCTION 92
TABLE 7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 92
TABLE 8 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 9 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 10 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 11 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 12 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION) 94
6.2 OLIGONUCLEOTIDE-BASED DRUGS 94
6.2.1 OLIGONUCLEOTIDE-BASED DRUGS DOMINATED MARKET IN 2021 94
TABLE 13 OLIGONUCLEOTIDE-BASED THERAPIES 94
TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 15 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 16 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 17 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 18 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 97
6.3 SYNTHESIZED OLIGONUCLEOTIDES 97
TABLE 19 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 21 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 99
6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT 99
TABLE 24 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 99
6.3.1.1 Primers 100
6.3.1.1.1 Increasing applications for oligo primers in DNA sequencing and molecular diagnostics to drive segment 100
TABLE 25 PRIMERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 26 PRIMERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 27 PRIMERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 28 PRIMERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 29 PRIMERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 102
6.3.1.2 Probes 102
6.3.1.2.1 Probes to detect various infectious agents and altered DNA/RNA sequences 102
TABLE 30 PROBES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 103
TABLE 31 PROBES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 32 PROBES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 33 PROBES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 34 PROBES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 105
6.3.1.3 DNA oligos 105
6.3.1.3.1 Innovations in DNA oligos to eliminate time-consuming PCR and drive segment 105
TABLE 35 DNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 105
TABLE 36 DNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 37 DNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 38 DNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 39 DNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 107
6.3.1.4 RNA oligos 107
6.3.1.4.1 RNA oligos to be used as molecular diagnostic tools 107
TABLE 40 RNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 107
TABLE 41 RNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 42 RNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 43 RNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 44 RNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 109
6.3.1.5 Other synthesized oligonucleotides 109
TABLE 45 OTHER SYNTHESIZED OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 110
TABLE 46 OTHER SYNTHESIZED OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 47 OTHER SYNTHESIZED OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 48 OTHER SYNTHESIZED OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 49 OTHER SYNTHESIZED OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 112
6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE 112
TABLE 50 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 112
6.3.2.1 Custom oligonucleotides 112
6.3.2.1.1 Surge in demand in clinical and preclinical studies to propel segment 112
TABLE 51 CUSTOM OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 113
TABLE 52 CUSTOM OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 113
TABLE 53 CUSTOM OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 54 CUSTOM OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 55 CUSTOM OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 114

6.3.2.2 Predesigned oligos 115
6.3.2.2.1 Predesigned oligos to be used in routine research applications, such as PCR and sequencing 115
TABLE 56 PREDESIGNED OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 115
TABLE 57 PREDESIGNED OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 58 PREDESIGNED OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 116
TABLE 59 PREDESIGNED OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 116
TABLE 60 PREDESIGNED OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 116
6.4 REAGENTS 117
6.4.1 GROWING APPLICATIONS OF OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO PROPEL MARKET 117
TABLE 61 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY REGION, 2020–2027 (USD MILLION) 117
TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 63 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 119
6.5 EQUIPMENT 119
6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO STIMULATE MARKET 119
TABLE 66 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY REGION, 2020–2027 (USD MILLION) 120
TABLE 67 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 68 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 69 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 70 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 121
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 122
7.1 INTRODUCTION 123
TABLE 71 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
TABLE 72 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
TABLE 73 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY REGION, 2020–2027 (USD MILLION) 124
TABLE 74 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 75 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 76 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 77 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 125
7.2 THERAPEUTIC APPLICATIONS 126
TABLE 78 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 126
TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 80 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 128
7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY TYPE 128
TABLE 83 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
7.2.1.1 Antisense oligonucleotide-based therapies 129
7.2.1.1.1 Antisense oligos to form basis of therapies in clinical trials 129
TABLE 84 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 129
TABLE 85 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 86 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 87 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 88 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 131
7.2.1.2 siRNA oligonucleotide-based therapies 131
7.2.1.2.1 Ease of drug target identification with bioinformatics to boost segment 131
TABLE 89 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 132
TABLE 90 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 132
TABLE 91 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 133
TABLE 92 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 133
TABLE 93 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 134
7.2.1.3 CpG oligonucleotide-based therapies 134
7.2.1.3.1 CpG ODNs to show significant potential for variety of disease treatments, including cancer 134
TABLE 94 CPG OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 134
TABLE 95 CPG OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 96 CPG OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 97 CPG OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 98 CPG OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 136
7.2.2 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE 136
TABLE 99 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 136
7.2.2.1 Neurological disorders 136
7.2.2.1.1 Neurological disorders dominated market by disease type in 2020 136
TABLE 100 NEUROLOGICAL DISORDERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 137
TABLE 101 NEUROLOGICAL DISORDERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 137
TABLE 102 NEUROLOGICAL DISORDERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 103 NEUROLOGICAL DISORDERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 104 NEUROLOGICAL DISORDERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 139

7.2.2.2 Infectious diseases 139
7.2.2.2.1 Antisense therapies and oligonucleotide aptamers to be significant in treatment and diagnosis of infectious diseases 139
TABLE 105 INFECTIOUS DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 140
TABLE 106 INFECTIOUS DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 107 INFECTIOUS DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 108 INFECTIOUS DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 109 INFECTIOUS DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 141
7.2.2.3 Other diseases 141
TABLE 110 OTHER DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 142
TABLE 111 OTHER DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 142
TABLE 112 OTHER DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 113 OTHER DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 114 OTHER DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 144
7.3 RESEARCH APPLICATIONS 144
TABLE 115 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 144
TABLE 116 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 145
TABLE 117 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 118 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 146
TABLE 119 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 146
TABLE 120 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 146
7.3.1 PCR 147
7.3.1.1 Increasing use of PCR in research to drive market 147
TABLE 121 PCR: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 147
TABLE 122 PCR: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 123 PCR: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 124 PCR: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 125 PCR: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 148
7.3.2 SEQUENCING 149
7.3.2.1 Advancements in technologies and low cost of DNA sequencing to boost segment 149
TABLE 126 SEQUENCING: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 149
TABLE 127 SEQUENCING: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 128 SEQUENCING: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 129 SEQUENCING: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 130 SEQUENCING: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 151
7.3.3 OTHER RESEARCH APPLICATIONS 151
TABLE 131 OTHER RESEARCH APPLICATIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 152
TABLE 132 OTHER RESEARCH APPLICATIONS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 133 OTHER RESEARCH APPLICATIONS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 134 OTHER RESEARCH APPLICATIONS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 135 OTHER RESEARCH APPLICATIONS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 153
7.4 DIAGNOSTIC APPLICATIONS 153
7.4.1 GROWING FIELDS OF MOLECULAR DIAGNOSTICS (MDX) AND IN VITRO DIAGNOSTICS (IVD) TO AUGMENT SEGMENT 153
TABLE 136 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 154
TABLE 137 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 154
TABLE 138 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 155
TABLE 139 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 155
TABLE 140 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 156

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 157
8.1 INTRODUCTION 158
TABLE 141 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 158
TABLE 142 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION) 158
TABLE 143 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 144 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 145 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 146 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION) 160
8.2 HOSPITALS 160
8.2.1 INCREASING FDA-APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS TO STIMULATE MARKET 160
TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 161
TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 161
TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 161
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 162
TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 162
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 162
8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY AND THERAPEUTICS TO DRIVE SEGMENT 162
TABLE 152 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 163
TABLE 153 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 163
TABLE 154 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 155 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 156 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 164
8.4 DIAGNOSTIC LABORATORIES 165
8.4.1 INCREASING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO STIMULATE GROWTH 165
TABLE 157 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 165
TABLE 158 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 166
TABLE 159 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 166
TABLE 160 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 166
TABLE 161 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 167
8.5 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS 167
8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO AID GROWTH 167
TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2020–2027 (USD MILLION) 168
TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 169
TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 169
8.6 ACADEMIC RESEARCH & INSTITUTES 169
8.6.1 ACADEMIC AND GOVERNMENT RESEARCHERS TO USE OLIGOS FOR GENOMIC TECHNOLOGIES 169
TABLE 167 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 170
TABLE 168 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 169 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 170 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 171
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 172
9.1 INTRODUCTION 173
TABLE 172 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2020–2027 (USD MILLION) 173
9.2 NORTH AMERICA 174
FIGURE 30 NORTH AMERICA: MARKET SNAPSHOT 174
TABLE 173 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 175
TABLE 174 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 175
TABLE 175 NORTH AMERICA: SYNTHESIZES OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 175
TABLE 176 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 176
TABLE 178 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 179 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 177
TABLE 180 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 177
TABLE 181 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 177
9.2.1 US 178
9.2.1.1 Government initiatives and strategic developments to drive market 178
TABLE 182 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 179
TABLE 183 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 179
TABLE 184 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 185 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 180
TABLE 186 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 187 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 180
TABLE 188 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 189 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 181

9.2.2 CANADA 181
9.2.2.1 Strong research infrastructure and availability of funding to support market 181
TABLE 190 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 182
TABLE 191 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 183
TABLE 192 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 193 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 183
TABLE 194 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 195 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 184
TABLE 196 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 197 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 185
9.3 EUROPE 185
TABLE 198 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 185
TABLE 199 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 186
TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 186
TABLE 201 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 202 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 187
TABLE 203 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 204 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 187
TABLE 205 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 206 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 188
9.3.1 UK 188
9.3.1.1 Increasing strategic developments by market players to propel market 188
TABLE 207 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 189
TABLE 208 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 190
TABLE 209 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 210 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 190
TABLE 211 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 212 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 191
TABLE 213 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 214 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 192
9.3.2 GERMANY 192
9.3.2.1 Presence of several academic & research institutes to aid growth 192
TABLE 215 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 193
TABLE 216 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 193
TABLE 217 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 218 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 194
TABLE 219 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 220 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 194
TABLE 221 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 222 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 195
9.3.3 FRANCE 195
9.3.3.1 Government initiatives to strengthen R&D activities and drive market 195
TABLE 223 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 196
TABLE 224 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 196
TABLE 225 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 226 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 197
TABLE 227 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 228 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 198
TABLE 229 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 230 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 198
9.3.4 ITALY 199
9.3.4.1 Increasing research activities in life sciences to boost market 199
TABLE 231 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 199
TABLE 232 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 200
TABLE 233 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 234 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 200
TABLE 235 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 201
TABLE 236 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 201
TABLE 237 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 201
TABLE 238 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 202
9.3.5 SPAIN 202
9.3.5.1 Government initiatives for development of biomedicine and healthcare sectors to stimulate market 202
TABLE 239 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 203
TABLE 240 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 203
TABLE 241 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 242 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 204
TABLE 243 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 244 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 204
TABLE 245 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 205
TABLE 246 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 205
9.3.6 REST OF EUROPE 205
TABLE 247 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 206
TABLE 248 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 206
TABLE 249 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 250 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 207
TABLE 251 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 252 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 207
TABLE 253 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 254 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 208
9.4 ASIA PACIFIC 208
FIGURE 31 ASIA PACIFIC: MARKET SNAPSHOT 209
TABLE 255 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 210
TABLE 256 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 210
TABLE 257 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 210
TABLE 258 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 259 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 211
TABLE 260 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 261 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 212
TABLE 262 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 212
TABLE 263 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 212
9.4.1 CHINA 213
9.4.1.1 Increasing focus of Chinese biopharma companies to aid market 213
TABLE 264 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 214
TABLE 265 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 214
TABLE 266 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 267 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 215
TABLE 268 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 215
TABLE 269 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 215
TABLE 270 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 271 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 216
9.4.2 JAPAN 216
9.4.2.1 Increasing awareness of oligos through conferences and workshops to drive market 216
TABLE 272 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 217
TABLE 273 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 217
TABLE 274 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 275 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 218
TABLE 276 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 277 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 219
TABLE 278 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 279 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 219
9.4.3 INDIA 220
9.4.3.1 Strong initiatives to develop bio clusters and increased adoption of genomic technologies to aid market 220
TABLE 280 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 220
TABLE 281 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 221
TABLE 282 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 221
TABLE 283 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 221
TABLE 284 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 285 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 222
TABLE 286 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 287 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 223
9.4.4 REST OF ASIA PACIFIC 223
TABLE 288 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 224
TABLE 289 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 224
TABLE 290 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 224
TABLE 291 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 225
TABLE 292 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 293 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 225
TABLE 294 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 226
TABLE 295 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 226
9.5 LATIN AMERICA 227
TABLE 296 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 227
TABLE 297 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 227
TABLE 298 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 228
TABLE 299 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 300 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 228
TABLE 301 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 302 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 229
TABLE 303 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 304 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 230
9.5.1 BRAZIL 230
9.5.1.1 Growing prevalence of infectious and non-infectious diseases to support market 230
TABLE 305 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 231
TABLE 306 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 231
TABLE 307 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 231
TABLE 308 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 232
TABLE 309 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 232
TABLE 310 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 232
TABLE 311 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 312 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 233
9.5.2 MEXICO 233
9.5.2.1 Increasing research in synthetic biology to drive market 233
TABLE 313 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 234
TABLE 314 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 234
TABLE 315 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 316 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 235
TABLE 317 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 235
TABLE 318 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 235
TABLE 319 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 320 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 236
9.5.3 REST OF LATIN AMERICA 237
TABLE 321 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 237
TABLE 322 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 237
TABLE 323 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 324 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 238
TABLE 325 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 326 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 239
TABLE 327 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 328 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 239
9.6 MIDDLE EAST & AFRICA 240
9.6.1 GROWING ACCEPTANCE OF PERSONALIZED MEDICINE TO PROPEL MARKET 240
TABLE 329 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 240
TABLE 330 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 241
TABLE 331 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 332 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 241
TABLE 333 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 242
TABLE 334 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 242
TABLE 335 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 242
TABLE 336 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 243
10 COMPETITIVE LANDSCAPE 244
10.1 INTRODUCTION 244
10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 244
TABLE 337 OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY STRATEGIES ADOPTED 244
10.3 MARKET SHARE ANALYSIS 245
FIGURE 32 OLIGONUCLEOTIDE SYNTHESIS MARKET: MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC MARKET), 2021 245
TABLE 338 OLIGONUCLEOTIDE SYNTHESIS MARKET (FOR RESEARCH AND DIAGNOSTIC MARKET): DEGREE OF COMPETITION 246
FIGURE 33 OLIGONUCLEOTIDE SYNTHESIS MARKET: MARKET SHARE ANALYSIS (THERAPEUTIC MARKET), 2021 247
TABLE 339 OLIGONUCLEOTIDE SYNTHESIS MARKET (FOR THERAPEUTICS MARKET): DEGREE OF COMPETITION 247
10.4 REVENUE ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET 248
FIGURE 34 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021) 248
10.5 COMPANY EVALUATION MATRIX 248
FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX, 2021 249
10.5.1 STARS 249
10.5.2 EMERGING LEADERS 250
10.5.3 PERVASIVE PLAYERS 250
10.5.4 PARTICIPANTS 250
10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES 251
FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021 251
10.6.1 PROGRESSIVE COMPANIES 251
10.6.2 STARTING BLOCKS 252
10.6.3 RESPONSIVE COMPANIES 252
10.6.4 DYNAMIC COMPANIES 252
10.7 COMPETITIVE BENCHMARKING OF START-UPS/SMES 252
TABLE 340 OLIGONUCLEOTIDE SYNTHESIS MARKET: DETAILED LIST OF KEY START-UPS/SMES 252
TABLE 341 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 253
10.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 253
10.8.1 COMPANY FOOTPRINT 253
TABLE 342 COMPANY FOOTPRINT ANALYSIS: KEY PLAYERS 253
10.8.2 PRODUCT FOOTPRINT 254
TABLE 343 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS 254
10.8.3 APPLICATION FOOTPRINT 255
TABLE 344 APPLICATION FOOTPRINT ANALYSIS: KEY PLAYERS 255
10.8.4 REGIONAL FOOTPRINT 256
TABLE 345 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS 256
10.9 COMPETITIVE SCENARIO AND TRENDS 257
10.9.1 PRODUCT LAUNCHES 257
TABLE 346 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT LAUNCHES (JANUARY 2019–OCTOBER 2022) 257
10.9.2 DEALS 258
TABLE 347 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS (JANUARY 2019–OCTOBER 2022) 258
10.9.3 OTHER DEVELOPMENTS 259
TABLE 348 OLIGONUCLEOTIDE SYNTHESIS MARKET: OTHER DEVELOPMENTS (JANUARY 2019–OCTOBER 2022) 259
11 COMPANY PROFILES 260
11.1 KEY PLAYERS 260
(Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View)*
11.1.1 DANAHER CORPORATION 260
TABLE 349 DANAHER CORPORATION: COMPANY OVERVIEW 260
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT 261
11.1.2 THERMO FISHER SCIENTIFIC INC. 265
TABLE 350 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 265
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 266
11.1.3 MERCK KGAA 269
TABLE 351 MERCK KGAA: COMPANY OVERVIEW 269
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT 270
11.1.4 EUROFINS SCIENTIFIC 272
TABLE 352 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 272
FIGURE 40 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 272
11.1.5 LGC LIMITED 274
TABLE 353 LGC LIMITED: COMPANY OVERVIEW 274
FIGURE 41 LGC LIMITED: COMPANY SNAPSHOT 275
11.1.6 AGILENT TECHNOLOGIES, INC. 278
TABLE 354 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 278
FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 279
11.1.7 KANEKA CORPORATION 281
TABLE 355 KANEKA CORPORATION: COMPANY OVERVIEW 281
FIGURE 43 KANEKA CORPORATION: COMPANY SNAPSHOT 282
11.1.8 MARAVAI LIFESCIENCES 285
TABLE 356 MARAVAI LIFESCIENCES: COMPANY OVERVIEW 285
FIGURE 44 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT 286
11.1.9 BIOLEGIO B.V. 288
TABLE 357 BIOLEGIO B.V.: COMPANY OVERVIEW 288
11.1.10 BIOLYTIC LAB PERFORMANCE INC. 289
TABLE 358 BIOLYTIC LAB PERFORMANCE INC.: COMPANY OVERVIEW 289
11.1.11 MICROSYNTH AG 290
TABLE 359 MICROSYNTH AG: COMPANY OVERVIEW 290
11.2 THERAPEUTIC PLAYERS 292
11.2.1 BIOGEN INC. 292
TABLE 360 BIOGEN INC.: COMPANY OVERVIEW 292
FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT 293
11.2.2 SAREPTA THERAPEUTICS, INC. 294
TABLE 361 SAREPTA THERAPEUTICS INC.: COMPANY OVERVIEW 294
FIGURE 46 SAREPTA THERAPEUTICS INC.: COMPANY SNAPSHOT 294
11.2.3 IONIS PHARMACEUTICALS, INC. 296
TABLE 362 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 296
FIGURE 47 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT 296
11.2.4 ALNYLAM PHARMACEUTICALS, INC. 298
TABLE 363 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 298
FIGURE 48 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT 298
* Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
11.3 OTHER PLAYERS 301
11.3.1 ADTBIO LTD. 301
11.3.2 TWIST BIOSCIENCE CORPORATION 301
11.3.3 ETON BIOSCIENCE, INC. 302
11.3.4 CSBIO 302
11.3.5 TAG COPENHAGEN A/S 303
11.3.6 GENERI BIOTECH 303
11.3.7 BIOCOMMA LIMITED 304
11.3.8 HONGENE BIOTECH CORPORATION 304
11.3.9 HANGZHOU PHARM &CHEM CO., LTD. 306
11.3.10 TOKYO CHEMICAL INDUSTRY CO., LTD. (TCI) 306
12 APPENDIX 307
12.1 DISCUSSION GUIDE 307
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 310
12.3 CUSTOMIZATION OPTIONS 312
12.4 RELATED REPORTS 312
12.5 AUTHOR DETAILS 313


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com